Radiation therapy and concurrent fixed dose @entity8503 with escalating doses of twice-weekly gemcitabine in advanced XXXX .

@entity1 @entity3123 @entity788 @entity137 @entity390 @entity882 @entity5 @entity8503 @entity391 @entity1398 @entity136
PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting @entity137 (DLT) of twice-weekly @entity136 (TW-G) when administered in conjunction with fixed dose @entity8503 (A) during external radiotherapy (RT) in @entity1 with advanced @entity788 . METHODS AND MATERIALS: Ten @entity1 with previously untreated, locally advanced, or asymptomatic-metastatic @entity788 were enrolled in this study. RT was delivered by using the standard four-field technique (1.8 Gy daily fractions, 45 Gy followed by a boost of 5.4 Gy, in 5-1/2 weeks). The starting dose of TW-G was 60 mg/m(2) (i.v., 30-min infusion), which is equal to the upper limit of previously reported MTD of TW-G when given without A during RT. A was given just before the TW-G, at a fixed dose of 340 mg/m(2) (i.v., rapid infusion). TW-G doses were escalated by 30-mg/m(2) increments in successive cohorts of 3 to 6 additional @entity1 until DLT was observed. @entity137 were graded using the Radiation Therapy Oncology Group and National @entity5 Institute Common @entity137 Criteria, version 2.0. RESULTS: In general, therapy was well tolerated in @entity1 treated at the first two dose levels of 60 mg/m(2) and 90 mg/m(2). The DLT of TW-G given in conjunction with A during RT were @entity1398 , @entity882 , and @entity390 / @entity391 at the dose level of 120 mg/m(2). Of the 10 @entity1 eligible for a median follow-up of 10 months, 5 remain alive; 1 complete responder, 3 partial responders, and 1 with stable disease. CONCLUSION: A dose of TW-G at a level of 90 mg/m(2) produced tolerable @entity137 and it may possess significant activity when delivered in conjunction with 340 mg/m(2) dose of A during RT of the upper abdomen. Due to the higher MTD of TW-G seen in our study, we consider that the A supplementation may optimize the therapeutic index of TW-G-based chemoradiotherapy protocols in @entity1 with @entity3123 .
